Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05421702
Other study ID # Soh-Med-22-06-17
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date April 2023

Study information

Verified date December 2022
Source Sohag University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will assess and compare Surgical, pathological and oncological outcomes between two laparoscopic procedures conventional colectomy versus complete mesocolic excision for operable colon cancer cases in Upper Egypt


Description:

Colon cancer is considered a huge clinical surgical burden accounting for 10% of cancer cases and deaths all over the world with consideration that surgery and adjuvant chemotherapy(if indicated) are the main lines of treatment . When Werner Hohenberger and colleagues described complete mesocolic excision (CME) in 2009; resection along the embryological and lymphovascular planes with appropriate resection margins, they did it for years before describing it with suggestion of improved disease outcomes and overall survival compared to the conventional colectomy (CC). The principles of CME were described after the significant improvement of rectal adenocarcinoma surgical outcomes with establishment of total mesorectal excision (TME) in which tumor resection is associated with dissection of mesorectal fascial embryologic and lymphovascular planes. CME includes the same principles of the CC with maximizing lymph node dissection level into (D3 extended lymphadenectomy instead of D1 and D2 in conventional colectomy) and central vascular ligation (CVL) of the main feeding vessel(s) at their origin, with suggested improved disease-free and overall survival with suggested superior pathological and oncological results in the specimen. Some surgeons consider that CME; with D3 extended lymphadenectomy and CVL is the optimal or standard surgical method in primary cancer colon based on suggested reduced local recurrence and improved disease-free and overall survival. Although CME has a theoretical advantages and promising early results, it is not widely adopted as the standard in some areas. CME is technically more demanding than CC and suggested to be associated with more intraoperative visceral injuries and non-surgical complications and many doubts persist about safety and efficacy of the procedure. The questions of interest and research, should CME be regarded as the optimal procedure for colon cancer cases? And also another question; is conventional colectomy suboptimal?


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date April 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Both sexes will be included. 2. Age: all adult patients. 3. All diagnosed patients with operable cancer colon. 4. Cancer at cecum, appendix, ascending colon, hepatic flexure or at splenic flexure, transverse and descending colon and sigmoid colon. 5. Fit patients. Exclusion Criteria: 1. Irresectable colon cancer. 2. Inoperable colon cancer. 3. Rectal cancer. 4. Unfit patients.

Study Design


Intervention

Procedure:
laparoscopic conventional colectomy
Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.
laparoscopic complete mesocolic excision
Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.

Locations

Country Name City State
Egypt Sohag faculty of medicine Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative lymph node status Histopathological examination of the resected colon with lymph node status and number 2 weeks postoperative
Primary Postoperative histopathological result Type of the colon cancer 2 weeks postoperative
Primary Occurence of anastomotic leak Yes/No within 4 weeks postoperative
Primary Amount of anastomotic leak Amount in cubic cm and nature of it with its management within 4 weeks postoperative
Primary Intraoperative visceral injury type Yes/No and its type Intraoperative reporting
Primary Intraoperative visceral injury management How managed Intraoperative reporting
Primary Postoperative complications Yes/No with Reporting the postoperative complications; according to the Clavien-Dindo Grading System 4 weeks postoperative
Primary Operative time Reporting operative time with measurements in minutes Reporting immediately postoperative (at end of operation)
Primary Intraoperative vascular injury Yes/No with measurement in Cubic Cm and how managed Intraoperative
Primary Intraoperative blood loss Yes/No with measurement in Cubic Cm Intraoperative
Primary Resection margins in postoperative histopathological status Free or invaded 2 weeks postoperative
Primary Postoperative peritonitis Cause and how to manage? 4 weeks postoperative
Primary Colon cancer stage According to primary tumor, regional nodes, metastasis (TNM) staging system 2 weeks Preoperative
Primary Postoperative faecal fistula Reporting Yes/No with amount in cm3 and management 12 weeks postoperative
Primary length of resected mesocolon In cm 2 weeks postoperative
Primary Urological complications Type and management Intraoperative and 4 weeks postoperative
Primary Carcinoembryonic antigen (CEA) level Carcinoembryonic antigen (CEA) level by ng/mL 2 weeks preoperative
Primary Type of anastomosis Type of anastomosis (intra- or extracorporeal) Intraoperative
Secondary Age In years preoperative
Secondary Preoperative haemoglobin level measured by g/dl preoperative
Secondary Type of colonic anastomosis Stapler or hand sewing Intraoperative
Secondary Preoperative histopathological result Histopathological examination 2 weeks preoperative
Secondary Neoadjuvant therapy Type of the neoadjuvant and duration 2 weeks Preoperative
Secondary Site of cancer colon cecum, appendix, ascending colon, hepatic flexure or at splenic flexure, transverse and descending colon and sigmoid colon 2 weeks preoperative
Secondary Neurological complications Type and management 4 weeks postoperative
Secondary Preoperative preparation Mechanical and/or chemical 3 days Preoperative
Secondary Cardiopulmonary complications Yes/No Cardiopulmonary complications type and how managed 4 weeks postoperative
Secondary Conversion to open surgery Yes/No with the cause intraoperative
Secondary application of subcutaneous suction Yes/No 1 week Postoperative
Secondary Average daily amount in subcutaneous suction in Milliliters 2 weeks Postoperative
Secondary Average daily amount in intraperitoneal drain in Milliliters 2 weeks Postoperative
Secondary Wound infection Yes/No and how managed 2 weeks postoperative
Secondary Postoperative ileus Postoperative ileus Yes/No 2 weeks postoperative
Secondary Hospital stay In days 4 weeks postoperative
Secondary Wound dehiscence Yes/No 4 weeks postoperative
Secondary Preoperative colonoscopic examination result mass/ulcer 2 weeks preoperative
See also
  Status Clinical Trial Phase
Completed NCT00309543 - Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B Phase 3
Recruiting NCT06434896 - Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial N/A
Recruiting NCT04089631 - Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation Phase 3
Recruiting NCT06108310 - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Recruiting NCT05194878 - Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers Phase 3